Is Microsclerotherapy Still the Gold Standard for Leg Thread Veins? A Review of the Evidence and Alternatives

By Dr. Haroun Gajraj | VeinCare Academy | 24th June 2026

This review is written for healthcare professionals who treat leg telangiectasia and reticular veins. It examines the current evidence and guideline positions on microsclerotherapy as first-line treatment, and reviews the principal alternatives and combination strategies: transdermal laser, intense pulsed light, radiofrequency thermocoagulation, and Cryo-Laser and Cryo-Sclerotherapy (CLaCS).

🎥 Prefer video? Watch the full review on YouTube: "Is Laser Better Than Microsclerotherapy? Leg Spider Vein Treatment Evidence" [→click here]

Contents

1. Introduction

2. Why microsclerotherapy remains first-line

3. Transdermal laser: a defined secondary role

4. Intense pulsed light: a niche option

5. Radiofrequency thermocoagulation as an adjunct: what the evidence shows

6. CLaCS: a specialist combination platform

7. A practical tiered framework for clinical decision-making

8. Key clinical points

9. References

1. Introduction

For most clinicians treating leg telangiectasia and reticular veins, microsclerotherapy is the starting point. It has been for decades. But the treatment landscape for CEAP C1 disease has become more complex in recent years. Device-based platforms are more accessible, combination strategies have accumulated trial-level evidence, and patients increasingly ask about alternatives to injection treatment.

The practical question for clinicians building or running a C1 service is not whether alternatives exist. They do. The question is which options have enough evidence to change clinical practice, and which patients benefit from something beyond standard injection treatment.

This article reviews the current evidence base and proposes a practical tiered framework for clinicians.

2. Why Microsclerotherapy Remains First-Line

Microsclerotherapy retains its position as the default treatment for leg telangiectasia and reticular veins because it satisfies the key criteria that any first-line treatment should meet: it is endorsed at the highest guideline level, supported by placebo-controlled trial data, broadly applicable, and achievable without specialist capital equipment.

The European Guidelines for Sclerotherapy in Chronic Venous Disorders give sclerotherapy a Grade 1A recommendation for both reticular veins and telangiectasias, and identify liquid sclerotherapy as the method of choice for C1 disease [1]. The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society (SVS/AVF/AVLS) Clinical Practice Guidelines recommend sclerotherapy with liquid or foam for symptomatic telangiectasias and reticular veins, reflecting the highest methodological standard in venous guideline development [2].

The EASI study, a double-blind randomised placebo-controlled trial, confirmed that active sclerosants outperform isotonic saline in telangiectasias and reticular veins and remains the benchmark efficacy reference for the field [3].

Beyond guideline endorsement and trial support, microsclerotherapy has two practical advantages that the alternatives do not fully replicate. First, it allows direct intraluminal treatment of both visible surface veins and feeder reticular veins within the same session and through the same technique. Second, its capital requirement is minimal compared with laser or combination platforms, which makes it available in a far wider range of clinical settings.

Its limitations are well established: hyperpigmentation, trapped blood, telangiectatic matting, and the rare but serious risks of extravasation injury and anaphylaxis. These limitations are the clinical rationale for exploring adjunctive and alternative strategies.

3. Transdermal Laser: A Defined Secondary Role

Transdermal laser, most commonly long-pulsed Nd:YAG (1064 nm), has a well-defined but secondary role in the treatment of leg telangiectasia. The SVS/AVF/AVLS 2023 guidelines specify the clinical circumstances in which it is recommended: sclerosant allergy, needle phobia, sclerotherapy failure, and small vessels under 1 mm with telangiectatic matting [2].

A prospective randomised trial by Parlar et al. comparing foam sclerotherapy with Nd:YAG laser for lower extremity telangiectasias found both treatments effective, but laser was more painful [4]. The authors highlighted its value in precisely those selected cases identified by the guidelines. A 2023 network meta-analysis suggested a relative advantage of Nd:YAG laser for telangiectasia clearance, though the study design and between-trial heterogeneity mean that this finding should not be interpreted as straightforward superiority across all clinical settings [5].

The capital and infrastructure cost of a dedicated Nd:YAG platform is considerably higher than microsclerotherapy. For most C1 presentations, that cost is difficult to justify when the injection pathway achieves comparable or superior results with greater flexibility and lower procedural cost.

The practical summary is that transdermal laser is a useful tool in a clinic's armamentarium, but the guidelines are right to position it as a selective alternative rather than a first-line standard.

4. Intense Pulsed Light: A Niche Option

Intense pulsed light (IPL) uses broad-spectrum filtered light absorbed by haemoglobin to create thermal vascular injury. It is already in use in many aesthetic clinics for facial vascular lesions, skin rejuvenation, and other indications, which makes it an accessible non-injection option where the platform is already available.

For leg telangiectasia specifically, the verified comparative evidence base remains limited. IPL cannot currently be positioned as equivalent or superior to microsclerotherapy for C1 leg veins on the strength of available primary data [5]. No major guideline in the current review gives it a formal recommendation for this indication.

Its most rational clinical use in leg C1 disease is as an adjunctive option in clinics with established IPL infrastructure, for patients who are not suitable for injection or laser treatment, or for very superficial red vessels that may respond to light-based photothermal injury. It should not be presented to patients as an equivalent alternative to microsclerotherapy on current evidence.

5. Radiofrequency Thermocoagulation as an Adjunct: What the Evidence Shows

The most clinically relevant new evidence in the C1 treatment landscape concerns radiofrequency (RF) thermocoagulation delivered as an adjunct to liquid sclerotherapy. A randomised pilot trial by Diken et al. (2021), published in Phlebology, randomised 111 patients with CEAP C1 spider veins to standard liquid sclerotherapy alone or to liquid sclerotherapy immediately followed by low-energy percutaneous RF thermocoagulation [8].

The combination group showed better patient-rated cosmetic outcomes, lower rates of hyperpigmentation and trapped blood, and required fewer total treatment sessions than the sclerotherapy-alone group. The proposed mechanism is that low-energy RF induces venous spasm immediately after sclerosant injection, reducing residual intraluminal blood and thereby lowering the substrate for haemosiderin deposition and pigmentation. Histological confirmation of this mechanism is not yet available, and the follow-up period in the Diken trial was short.

There are important limits to how far this evidence can be extrapolated. The trial enrolled patients with isolated C1 spider veins and specifically excluded patients with axial reflux and larger feeder veins over 1 mm. Procedure time per session was substantially longer in the combination group. No head-to-head trial comparing RF-assisted microsclerotherapy with CLaCS has been identified in the published literature, so the comparison between these two combination approaches remains indirect.

The practical implications are real nonetheless. For clinics that already perform injection-based treatment and are looking for an evidence-supported step to reduce pigmentation and improve cosmetic satisfaction in selected isolated spider-vein cases, RF thermocoagulation represents a lower-capital, injection-centred combination pathway that is more accessible than a full CLaCS platform. It is best understood as a credible adjunct rather than a replacement for standard microsclerotherapy, and its role in cases with feeder veins or more complex disease patterns is not yet defined.

RF thermocoagulation at 4 MHz is used in the treatment of facial spider veins as well as in combination with microsclerotherapy for leg telangiectasia. Both applications are covered in VeinCare Academy training.

6. CLaCS: A Specialist Combination Platform

Cryo-Laser and Cryo-Sclerotherapy, or CLaCS, combines external Nd:YAG laser photothermolysis, simultaneous skin cooling, and immediate intraluminal chemical sclerosis. It is designed to address both the surface telangiectasia and the feeding reticular network in a single coordinated session.

Two recent randomised trials support its clinical efficacy. A 2023 randomised trial by Cordeiro et al. assessed combined Nd:YAG laser plus injection sclerotherapy using two sclerosant protocols and found both safe and effective [7]. A 2024 randomised trial by Nasser et al. reported that CLaCS was superior to conventional sclerotherapy for telangiectasia and reticular veins, providing the strongest direct superiority signal among the combination approaches reviewed here [6].

CLaCS is not currently available in most UK aesthetic or phlebology clinics. It requires Nd:YAG laser infrastructure, a cooling system, and dual-modality operator expertise, making it a specialist-centre option rather than an accessible service-line addition for most practitioners. It is most appropriate for mixed telangiectatic-reticular presentations, treatment-resistant disease, and selected recurrences in centres with the necessary equipment and training. Clinicians encountering patients who may benefit from CLaCS should be aware of specialist referral pathways, but it is not a realistic first-line or near-term addition to most C1 services.

7. A Practical Tiered Framework for Clinical Decision-Making

The totality of the current evidence supports a three-tier approach to C1 disease, organised by the clinical presentation and the available infrastructure.

First line for most patients: microsclerotherapy. Standard liquid microsclerotherapy remains the default for the vast majority of patients presenting with leg telangiectasia and reticular veins. It offers guideline-endorsed, trial-supported efficacy, the ability to treat feeder veins, and no significant capital barrier. It should be the starting point for any C1 service and the benchmark against which other options are judged.

Selective alternatives and adjuncts: Transdermal Nd:YAG laser is appropriate for needle-phobic patients, very fine vessels under 1 mm, sclerosant intolerance, and telangiectatic matting. RF thermocoagulation as an adjunct to liquid sclerotherapy is a credible option for selected isolated C1 spider veins where reducing hyperpigmentation and trapped blood is a priority, particularly in patients with a previous history of troublesome pigmentation. IPL has a niche role in clinics with established platforms, for suitable patients who are not candidates for injection or laser treatment. None of these replaces microsclerotherapy as the standard; they complement or extend its reach in specific clinical scenarios.

Specialist referral: CLaCS. For patients with mixed telangiectatic-reticular networks, treatment-resistant disease, or complex recurrent presentations where a specialist combination platform would be advantageous, CLaCS should be considered as a specialist-centre option. Most patients do not need this level of resource, and the absence of a head-to-head comparison between CLaCS and RF-assisted microsclerotherapy means that treatment selection in complex cases should currently be driven by case pattern, available expertise, and patient priorities rather than by evidence of definitive superiority between the two approaches.

8. Key Clinical Points

- Microsclerotherapy remains the best-supported first-line treatment for leg telangiectasia and reticular veins, with Grade 1A guideline endorsement and placebo-controlled trial evidence [1][2][3].

- Transdermal Nd:YAG laser has a defined secondary role for needle phobia, sclerosant intolerance, very fine vessels, and telangiectatic matting [2][4].

- IPL has a niche non-injection role for leg telangiectasia; the verified comparative evidence base for this indication remains limited and it does not carry guideline endorsement for C1 leg veins [5].

- RF thermocoagulation added to liquid sclerotherapy improved cosmetic outcomes, reduced hyperpigmentation, and reduced session numbers in a pilot RCT of selected isolated C1 spider veins; procedure time per session was longer [8].

- RF-assisted microsclerotherapy is best understood as an evidence-supported adjunctive step for selected cases rather than a replacement for standard first-line treatment.

- CLaCS has the strongest direct superiority evidence over conventional sclerotherapy among the combination approaches reviewed, but it requires specialist-centre infrastructure and is not available in most UK aesthetic or phlebology clinics [6][7].

- No direct head-to-head trial comparing RF-assisted microsclerotherapy with CLaCS has been published; the comparison between these two combination strategies remains indirect [6][7][8].

- For most C1 services, the practical hierarchy is: microsclerotherapy as the default, selective laser or RF-assisted adjuncts where clinically indicated, and CLaCS as a specialist referral pathway.

*9. References

1. Rabe E, Breu FX, Cavezzi A, et al. European guidelines for sclerotherapy in chronic venous disorders. Phlebology. 2014;29(6):338–354. https://pubmed.ncbi.nlm.nih.gov/23559590/

2. Gloviczki P, Lawrence PF, Gibson K, et al. The 2023 SVS/AVF/AVLS clinical practice guidelines for the management of varicose veins of the lower extremities. Part II. J Vasc Surg Venous Lymphat Disord. 2024;12(1):101670. https://pubmed.ncbi.nlm.nih.gov/37652254/

3. Rabe E, Schliephake D, Otto J, Breu FX, Pannier F. Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology. 2010;25(3):124–131. https://pubmed.ncbi.nlm.nih.gov/20483861/

4. Parlar B, Blazek C, Cazzaniga S, et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. J Eur Acad Dermatol Venereol. 2015;29(3):549–554. https://pubmed.ncbi.nlm.nih.gov/25069999/

5. Bontinis V, Bontinis A, Koutsoumpelis A, et al. Interventions for the treatment of lower limb telangiectasias and reticular veins: a systematic review and network meta-analysis. Eur J Vasc Endovasc Surg. 2023;66(4):560–576. https://pubmed.ncbi.nlm.nih.gov/37209995/

6. Nasser MM, Ghoneim BM, Eldaly W, Elmahdy H. A comparative study between cryo-laser cryo-sclerotherapy and sclerotherapy in the treatment of telangiectasia and reticular veins: a randomized controlled trial. J Vasc Surg Venous Lymphat Disord. 2024;12(4):101874. https://pubmed.ncbi.nlm.nih.gov/38522666/

7. Cordeiro RGM, de Godoy JMP, da Silva ES, et al. Nd:YAG laser combined with injection sclerotherapy in the treatment of reticular veins and telangiectasias (CLaCS method): a triple-blind randomized clinical trial comparing two sclerosing agents associated with same laser patterns. Phlebology. 2023;38(3):165–171. https://pubmed.ncbi.nlm.nih.gov/36657386/

8. Diken AI, Alemdaroglu U, Ozyalcin S, et al. Adjuvant radiofrequency thermocoagulation improves the outcome of liquid sclerotherapy in the treatment of spider veins of the leg: a pilot study. Phlebology. 2021;36(8):620–626. https://doi.org/10.1177/02683555211006534

---

Microsclerotherapy Training

VeinCare Academy offers training in microsclerotherapy, radiofrequency thermocoagulation at 4 MHz (including its application in facial spider veins), and the combination of microsclerotherapy and RF thermocoagulation for leg telangiectasia. Details of current courses are available at veincare.academy.

---

About the Author Dr Haroun Gajraj

This educational article is written and regularly reviewed by Dr Haroun Gajraj, a GMC-registered vein specialist who has treated thousands of patients with vein disease and has trained many doctors and nurses in microsclerotherapy, radiofrequency thermocoagulation, and related cosmetic vein procedures. Dr Gajraj is the founder and board member of the British Association of Sclerotherapists. You can view his current GMC registration and independent patient reviews on iWantGreatCare for further information about his clinical background.

This article is intended for healthcare professionals and is based on current clinical guidelines, peer-reviewed research, and day-to-day practice experience. The information here is general education only and is not a substitute for individual clinical judgement, local protocols, or formal training. Clinicians remain responsible for assessing each patient, obtaining informed consent, explaining risks and alternatives, and working within the scope of their professional registration and regulatory guidance.

Subscribe

For regular updates get my weekly newsletter here

© VeinCare Academy | Dr. Haroun Gajraj | veincare.academy
This article is intended for qualified healthcare professionals. All clinical decisions should be based on individual patient assessment, primary medical literature and current professional guidelines.

*All references in this blog have been checked against publicly available sources (for example, PubMed and official guideline websites), but this is an educational blog post, not a peer-reviewed journal article. Minor discrepancies in author lists, page numbers or indexing details may remain, and readers should always refer to the original publications and current clinical guidelines before making clinical decisions.